To hear about similar clinical trials, please enter your email below

Trial Title: PINPOINT Feasibility Study

NCT ID: NCT05481372

Condition: Prostate Cancer
Image Guided Radiotherapy

Conditions: Official terms:
Prostatic Neoplasms

Study type: Interventional

Study phase: N/A

Overall status: Unknown status

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Intervention model description: Single centre feasibility study

Primary purpose: Other

Masking: None (Open Label)

Intervention:

Intervention type: Other
Intervention name: Imaging
Description: Trans-perineal ultrasound and Magnetic resonance image acquisition
Arm group label: Standard radiotherapy with research image acquisition

Summary: This feasibility study is investigating the application of magnetic resonance imaging (MRI) and transperineal ultrasound (TPUS) to visualise potential sites of relapse and surrounding normal tissue in patient having post-operative prostate cancer radiotherapy. Structure visualisation on MRI and TPUS will be compared to current standard computer tomography (CT) and cone-beam computer tomography (CBCT) imaging.

Detailed description: Approximately 47,000 men are diagnosed with prostate cancer yearly in the UK, 15% of which receive surgery (radical prostatectomy) as primary treatment. Of these men one third develop recurrence after prostatectomy and are offered post-operative radiotherapy. Radiotherapy is targeted at the area where the prostate used to be, this includes potential relapse sites (PRS); vesicourethral anastomosis, bladder neck and retrovesicle space. When planning post-operative radiotherapy, the lack of a visible target means surrounding normal tissue is used to guide clinical target volume (CTV) delineation. The CTV is the area of tissue to be treated to the full radiotherapy prescription and includes PRS. Typically, the CTV is defined on a radiotherapy planning computer tomography (CT) scan. The CTV lies adjacent to the bladder and rectum and is highly susceptible to positional changes influenced by organ filling. To identify and correct for CTV displacement during daily radiotherapy a cone-beam CT (CBCT) is acquired, this is an image similar to a CT scan but taken immediately prior to treatment delivery. CT visualisation of PRS has been reported as inadequate, increasing the risk of missing or miss-identifying CTV structures during radiotherapy planning and delivery. To compensate for restricted visualisation on CT and CBCT an additional 1cm circumference around the CTV is treated to the prescription dose, this volume is referred to as the planning target volume (PTV). This margin reduces the risk of missing the target however its inclusion of normal tissue increases the risk of patient toxicity. We propose that visualisation of PRS and surrounding normal tissue structures is enhanced on magnetic resonance imaging (MRI) compared to CT and on transperineal ultrasound (TPUS) compared to CBCT. This project investigates the reality of this statement by quantifying the confidence and reliability with which anatomical structures can be identified and delineated on all four image types.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Patient has undergone radical prostatectomy - Histologically confirmed prostate cancer - Patient due to receive post-operative prostate bed +/- pelvic lymph node radiotherapy - WHO performance status 0-1 - Age ≥ 18 years - Written informed consent Exclusion Criteria: - Recruitment into POPS trial - Contraindications to MRI such as having a pacemaker or non-MRI compatible implanted device

Gender: Male

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Sophie Alexander

Address:
City: Sutton
Zip: kt5 8hx
Country: United Kingdom

Status: Recruiting

Contact:
Last name: Sophie Alexander

Phone: 020 8915 6053
Email: sophie.alexander@rmh.nhs.uk

Contact backup:
Last name: Julia Murray
Email: julia.murray@icr.ac.uk

Start date: August 2022

Completion date: December 2023

Lead sponsor:
Agency: Royal Marsden NHS Foundation Trust
Agency class: Other

Source: Royal Marsden NHS Foundation Trust

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05481372

Login to your account

Did you forget your password?